Survival data showed that NR0B2 expression is a favorite prognosis factor in patients with liver, kidney, lung, urinary bladder cancers but is a negative factor in patients with colon, thyroid, uterine, and head-neck cancers. This evidence concerns the gene NR0B2 and head and neck cancer.